Total and out-of-pocket costs of different primary management strategies in ovarian cancer

Abstract Background Communicating healthcare costs to patients is an important component of delivering high-quality value-based care, yet cost data is lacking. This is especially relevant for ovarian cancer, where no clinical consensus on optimal first-line treatment exists. Objective The objective of this study was to generate cost estimates of different primary management strategies in ovarian cancer. Study Design All women who underwent treatment for ovarian cancer from 2006-2015 were identified from the MarketScan database (n=12,761) in this observational cohort study. Total and out-of-pocket costs were calculated using all claims within 8 months from initial treatment and normalized to 2017 US dollars. The generalized linear model method was used to assess cost by strategy. Results Among patients who underwent neoadjuvant chemotherapy and those who underwent primary debulking, mean adjusted total costs were $113,660 and $107,153 (p Conclusions Costs vary across different treatment strategies and patients bear a significant out-of-pocket burden, especially those enrolled in high-deductible health plans.